A Phase 1/2 Study Of REGN5093 In Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Brief description of study

The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug), and effectiveness of investigational drug REGN5093. There are additional purposes of this study including measurement of the levels of REGN5093 in your blood, and collection of any evidence of tumor shrinkage. REGN5093 is a human bispecific antibody (bsAb) that binds to cells in the body. “Investigational” means that the drug is new and is being studied to see if it is safe and effective. It also means that REGN5093 is not approved for use by the U.S. Food and Drug Administration (FDA). Therefore, it can only be used in a research study such as this one.

Clinical Study Identifier: s19-00641
ClinicalTrials.gov Identifier: NCT04077099
Principal Investigator: Joshua K Sabari.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.